Drug Reimbursement & Patient Assistance Programs

ANCO acknowledges the assistance of Lash Group Healthcare Consultants for their help in compiling this information. For additional information, also visit:

American Society of Clinical Oncology (ASCO)
www.asco.org/asco/downloads/PhRMA_Brochure.pdf

Chronic Disease Fund
www.cdfund.org

HealthWell Foundation
www.healthwellfoundation.org

National Organization for Rare Disorders
www.rarediseases.org

National Patient Advocate Foundation
www.colorectalcareline.org
www.copays.org
www.patientadvocate.org

NeedyMeds
www.needymeds.com

Partnership for Prescription Assistance
www.helpingpatients.org

Patient Access Network Foundation
www.patientaccessnetwork.org

Patient Services Incorporated
www.uneedpsi.org

Abraxis Oncology
ARC of Support
(800) 564-0216;
Abraxane
The ARC of Support is a comprehensive program that provides a broad range of services (i.e., medical information, reimbursement and patient assistance, drug safety, product quality) for healthcare professionals caring for patients undergoing treatment with Abraxane.

Abraxis Patient Access Program (APAP)
(800) 564-0216, option 3;
8:00AM-8:00PM Eastern Time
Abraxane
APAP consists of two components—one for insured patients that have been treated with Abraxane where claims have been denied by their insurers, and the other for uninsured patients that receive treatment with Abraxane. More information can be obtained at www.abraxane.com.

Allos Support for Assisting Patients (ASAP)
Monday–Friday, 9:00 am–8:00 pm, ET
1-877-ASAP102 (877-272-7102) - phone
1-877-801-0777 – fax

www.getASAPinfo.com

Allos Therapeutics, Inc. proudly sponsors the Allos Support for Assisting Patients
(ASAP) program, a reimbursement support and patient assistance program
designed to help patients and healthcare professionals gain appropriate access to
FOLOTYN® (pralatrexate injection). The ASAP program provides the following
services:
• Verification of Patient-Specific Insurance Benefits
• Pre-Submission Claims Review and Support
• Prior Authorization Assistance
• Coding and Billing Guidance
• Payer Research
• Denied and Underpaid Claims Assistance
• Patient Assistance Program for Qualified Patients
Allos Therapeutics, Inc. does not guarantee coverage and/or reimbursement for FOLOTYN. Coverage, coding, and
reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and
reimbursement decisions are made by individual payers following the receipt of claims. Allos strongly recommends
verifying coverage, coding, and reimbursement guidelines on a payer and patient-specific basis.

AMGEN
The SAFETY NET Foundation
(888) 762-6436;
FAX (877) 549-7239;
9:00AM-8:00PM Eastern Time
Aranesp, Epogen, Neulasta, Neupogen, Nplate, Sensipar, Vectibix
The Foundation helps qualified uninsured patients with limited or no financial resources and in limited cases qualified underinsured patients obtain access to AMGEN products. Patients apply for assistance through sponsoring health care professionals.

ENcourage Foundation
(888) 4Enbrel;
FAX (888) 508-8083;
8:00AM-8:00PM Eastern Time
Enbrel
The Foundation helps qualified, uninsured patients with limited or no financial resources obtain access to Enbrel.

AMGEN’s Reimbursement Connection
(800) 272-9376;
FAX (888) 508-8090
9:00AM-8:00PM Eastern Time
The Reimbursement Connection provides help to take the confusion out of reimbursement, coverage, and patient assistance. Online assistance with insurance verification, patient assistance, and billing/claims support is available.

Amgen corporate website link: www.amgen.com

Patient Assistance Programs:
Amgen Assist® gives patients and healthcare professionals a single destination for access to
eService and online forms, and makes it easier to find a program that would best meet each
patient's unique needs, including coverage and reimbursement services, co‐pay support
information, and assistance for uninsured patients. Please contact us at (888) 4ASSIST
(888‐427‐7478), or visit us at www.amgenassistonline.com.

Prior Authorization and Reimbursement Assistance:
Amgen Assist® gives patients and healthcare professionals a single destination for access to
eService and online forms, and makes it easier to find a program that would best meet each
patient's unique needs, including coverage and reimbursement services, co‐pay support
information, and assistance for uninsured patients. Please contact us at (888) 4ASSIST
(888‐427‐7478), or visit us at www.amgenassistonline.com.

AstraZeneca
AstraZeneca Cancer Support Network (AZ CSN)
(866) 922-9276;
FAX (866) 279-0709;
8:00AM-8:00PM Eastern Time
Arimidex, Casodex, Faslodex, Zoladex
AZ CSN is a comprehensive service platform for physicians and patients designed to meet informational needs, provide access to product, and address coverage issues. Specially trained Registered Nurses, Pharmacists, and Reimbursement Specialists are available to personally address customer needs including a gateway to the AZ & Me Prescription Savings Program. More information can be obtained by visiting www.azcsn.net.

 

Bayer Healthcare Pharmaceuticals/Onyx Pharmaceuticals

Nexavar REACH Program
(866) NEXAVAR (639-2827);
FAX (866) 639-5181;
9:00AM-8:00PM Eastern Time
Nexavar
The Program provides clinical information, insurance information, reimbursement support, prescription processing, and patient assistance to uninsured patients who meet the program eligibility criteria.

 

biogenIDEC
RESULTS
(800) 386-9997;
FAX (800) 513-8095;
9:00AM-6:00PM Eastern Time
Zevalin
RESULTS (REimbursement SUpport Line Trained Specialists) provides access to Zevalin for patients who meet the program’s eligibility criteria and reimbursement counseling to patients and their healthcare providers.

Single Point of Contact (SPOC)
(888) 249-4918;
FAX (888) 249-4919;
9:00AM-5:00PM Pacific Time
Rituxan
SPOC investigates benefits for new patients and those changing insurance or facing open enrollment; assists with coverage paperwork (e.g., prior authorization, medical reviews); helps with appeals and coverage denials; searches for alternative coverage for patients whose insurers do not provide adequate coverage; answers reimbursement questions; consults on coding and billing issues; tracks insurance claims; and, provides information on uninsured patient programs.

Zevalin Concierge Program
(866) 298-8433;
FAX (877) 264-8483;
8:30AM-8:00PM Eastern Time
Zevalin
The Program verifies insurance benefits and addresses reimbursement concerns; obtains patient assistance details and provides follow-up; assists with scheduling; coordinates financial assistance when needed; tracks claims from submission to payment; provides access to medical information and assists with technical product information; and, serves as a point of contact for each physician and staff member involved in treatment.

bioTheranostics
bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in genomic profiling and proprietary algorithms, bioTheranostics provides innovative tests to the oncology community that help drive personalized treatment. The company operates a CLIA-certified, CAP-accredited, diagnostic service laboratory in San Diego, California, to perform its proprietary molecular diagnostic tests: CancerTYPE ID®, a molecular cancer classifier particularly helpful for patients diagnosed with metastatic cancer whose tumor origin is either uncertain or unknown through conventional diagnostic testing; and the Breast Cancer Index®, which refines and improves risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. More information is available at www.biotheranostics.com.

Wendy Johnson
Associate Director Marketing
bioTheranostics
858-587-5887

 

 

Bristol-Myers Squibb Oncology
Destination Access
(800) 861-0048;
FAX (888) 776-2370;
8:00AM-8:00PM Eastern Time
(Reimbursement specialists available live Monday through Friday)
All Bristol-Myers Squibb Oncology products
Destination Access provides prior authorization assistance, appeals assistance, benefits investigation, general reimbursement guidance, and patient assistance.

 

Celgene
Innohep Support Services
(866) 742-7646
Innohep
Innohep Support Services provides reimbursement and patient assistance support.

Patient Support Coordinator (PSC) Program
(800) 931-8691;
FAX (800) 822-2496;
www.celgenepsc.com;
patientsupport@celgene.com
5:00AM-4:00PM Pacific Time
The Celgene Patient Support Coordinator (PSC) Program was created to help patients and healthcare providers navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Celgene products and their distribution. The PSC is a dedicated central point of contact who assists providers and patients who rely on Celgene products. The RevAssist/STEPS telephone number is (888) 423-5436.

Vidaza Support Services
(866) 742-7646;
FAX (866) 369-4333;
8:00AM-8:00PM Eastern Time
Vidaza
Vidaza Support Services provides reimbursement and patient assistance support.

 

Eisai
Eisai Reimbursement Assistance Program
(877) 644-6270;
FAX (888) 644-7236;
8:00AM-8:00PM Eastern Time
Aloxi, Dacogen, Gliadel, Hexalen, Salogen
(866) 613-4724;
FAX (866) 573-4724;
Ontak, Panretin, Targretin
(866) 272-8804;
FAX (866) 272-8805;
Fragmin
The Eisai Reimbursement Assistance Program provides patient assistance and reimbursement support for Aloxi, Dacogen, Fragmin, Gliadel, Hexalen, Ontak, Panretin, Salogen, and Targretin. A customer service representative will assist with Eisai product information, indigent programs, reimbursement questions, prior authorizations, referral to co-pay assistance programs, insurance verification, billing/coding questions, appeal assistance, referral to disease-state assistance programs and letters of medical necessity.

 

Genentech BioOncology
Genentech Access Solutions
(888) 249-4918;
www.genentechaccesssolutions.com;
Avastin, Herceptin, Rituxan, Tarceva
Genentech Access Solutions provides one-stop access to a broad array of reimbursement information, and support and services for patients so that they can focus on treatment. In addition to providing information about co-pay assistance through independent public charities, Genentech Access Solutions can also help with common reimbursement challenges, insurance appeals and coverage denials, and referrals to the Genentech Access to Care Foundation. For coverage and reimbursement services, visit www.genentechaccesssolutions.com/
docs/av/ASEEnrollment.pdf
for patient assistance, visit www.genentechaccesssolutions.com/
docs/av/GATCFEnrollment.pdf
.

Avastin Patient Assistance Program
(888) 249-4918;
FAX (888) 249-4919;
6:00AM-5:00PM Pacific Time
The Avastin Patient Assistance Program is designed to limit the overall annual cost of Avastin for eligible patients receiving treatment for FDA-approved indications. Participation in the Program provides a voluntary opportunity for physicians and eligible patients who reach an annual charge of 10,000mg to receive free Avastin from Genentech for the remainder of the 12-month period. The Program is open to all patients receiving Avastin (regardless of insurance coverage) with a household adjusted gross income of up to $100,000. Patients must be receiving Avastin for an FDA-approved indication.

 

Genzyme Oncology
Clolar Direct Response Program
(800) RX-CLOLAR (800-792-5652);
FAX (866) 617-3001;
www.clolar.com/hcp/resources/cl_hc_re_direct.asp
9:00AM-5:00PM EST
Clolar
This support program provides a one-stop information resource for reimbursement and patient access questions. Staffed with specialists with expertise in public and private health insurance, the program offers assistance in securing payer coverage requirements, providing coding and billing information, verifying patient benefits, and accessing patient assistance resources.

 

GlaxoSmithKline Oncology
Tykerb Cares
(866) 489-5372;
www.tykerb.com
Tykerb
The Tykerb Cares support program helps patients and the healthcare providers who treat them. All patients who are prescribed Tykerb are eligible for the Tykerb Cares program. It is a one stop point of contact for arranging to have your prescription filled through a specialty pharmacy, researching your insurance coverage, including benefits verification, determining the lowest co-pay available, alternative coverage options, accessing the patient assistance program, and obtaining enrollment forms for Tykerb.

GSK Reimbursement Resource Center
(800) 745-2967;
www.rrc.gsk.com
The GSK Reimbursement Resource Center is a toll-free reimbursement support program available to assist patients and healthcare professionals in the United States with drug coverage, coding, and reimbursement issues for certain GSK products.

Commitment to Access
www.commitmenttoaccess.com
Commitment to Access, GlaxoSmithKline’s patient assistance program for oncology medicines, provides GSK prescription medicines to eligible low-income patients without third party prescription drug benefits. Enrollment forms and information can be obtained at www.commitmenttoaccess.com.

 

ImClone Systems
BMS/ImClone Destination Access
(800) 861-0048;
FAX (888) 776-2370;
www.destinationaccess.com;
7:00AM-7:00PM
Erbitux
The BMS/ImClone Destination Access program helps with benefit investigation (appeals for physicians and patients, pre- & post-treatment appeals, Medicare Part B appeals, appeal FAQs) and patient assistance.

 

Lilly Oncology
Lilly Patient One
(866) 4PatOne;
FAX (866) 472-8663
Alimta, Gemzar
Lilly Oncology’s Patient One program provides reliable and individualized treatment support that addresses financial, access, and claim issues for patients who are candidates for Lilly’s oncology products. More information is available at www.lillypatientone.com/index.jsp.

 

Millennium
Velcade Reimbursement Assistance Program
(866) VELCADE;
9:00AM-8:00PM Eastern Time
Velcade
The Program provides product, clinical trials, and reimbursement information.

 

Novartis Oncology

Patient Assistance and Reimbursement Programs
Reimbursement Hotline: 800-282-7630
Patient Assistance Programs: 866-884-5906

Novartis is committed to providing access to our medications for those most in need. Through a variety of resources, including the Novartis Oncology Patient Assistance Program, the Novartis Oncology Reimbursement Hotline, and our support of independent Charitable Copay foundations, we have made a firm commitment to enable patients in need to access medicines.

Visit www.novartisoncology.us for complete patient assistance, reimbursement and clinical trail information. (This will link directly to Access to Medicine page)

 

Oncology Supply/ION
(888) 536-7697
OS/ION offers a unique value to pharmaceutical companies, service providers, and physician practices. Access provided by OS/ION empowers health care providers and industry companies to improve the efficiency, effectiveness, and quality of health care delivery to patients while enabling them to satisfy their respective missions. The collective portfolio of services and solutions from OS/ION include OS/ION Coding Workshops, monthly Web/teleconference workshops specifically for OS/ION members, which address pertinent topics such as basic coding rules and standards, and evaluation and management documentation requirements; OS/ION Medical Advisory Panel (MAP), comprising industry thought leaders with collective expertise in disease states, community-based practice, and business administration with an ongoing mission to deliver quality pharmaceutical products to patients as well as creative practice solutions to physicians; OS/ION Protocol Analyzer, a preloaded software program, complete with standard drug pricing from Oncology Supply and CMS’s most recent reimbursement data, which is available online at www.iononline.com, and calculates the overall cost of delivering chemotherapy in the practice; the OS/ION Pharmacy & Dispensing Program, with two distinct drug dispensing models that can be used to distribute medication for payment under the pharmacy benefits portion of a patient’s insurance and enables close analysis of each practice’s prescription-writing habits to determine which model is most suitable for use; OS/ION Practice Reimbursement Series, a series of reimbursement webinars that are designed to help network members stay abreast of breaking issues related to reimbursement and how it impacts them; OS/ION Vital Reimbursement Resources, a feature on the OS/ION Web site through which members are directed to an array of reimbursement material including CMS and Medicare enrollment forms, and timely news updates pertaining to reimbursement and legislation are posted in this section; and the overall OS/ION GPO Function, whereby the country’s largest diversified services organization for the community-based practitioner is designed to contract directly with pharmaceutical and biotech companies to support their products within the organization’s membership.

 

Onmark, McKesson Specialty Care Solutions
Regimen Profiler
(866) 686-8340
Onmark, McKesson Specialty Care Solutions, is the leading national group purchasing organization for community-based practices. Onmark delivers cost savings through its premier contract portfolio, plus innovative business and clinical solutions that empower members to operate more efficiently and deliver cost-effective, high-quality patient care.

Regimen Profiler is a Web-based tool that helps oncology practices and their patients understand financial and clinical information for many oncology treatment regimens. It is available free of charge to Onmark members. Visit www.onmarkservices.com and click on the Practice Management tab to learn more.

 

Ortho Biotech
DOXILine
(800) 609-1083;
FAX (800) 987-5572;
www.DOXILine.com;
9:00AM-8:00PM Eastern Time
Doxil
DOXILine provides access to reimbursement information and support—patient assistance program to patients without insurance coverage (based on financial need); access to insurance guidelines for private, federal, and state plans; verification of insurance coverage; and, coding and billing assistance.

ProcritLine
(800) 553-3851;
FAX (800) 987-5572;
www.procritline.com;
9:00AM-8:00PM Eastern Time
Leustatin, Procrit
ProcritLine provides easy access to reimbursement information and support—patient assistance program to patients without insurance coverage (based on financial need), coding and billing assistance, verification of insurance coverage, and assistance with appeals.

 

OSI Pharmaceuticals
(866) 435-2524;
Gelclair
(866) 374-8906;
Novantrone
(888) 249-4918;
Tarceva
These hotlines provide medical information and patient assistance.

Pathwork  Diagnostics                                                                          
1-877-808-0006, option 5                        
The Tissue of Origin Test
Reimbursement and Patient Assistance Programs
9:00am-5:50am, EST
Reimbursement and Patient Assistance Programs

Tissue of Origin Test – Pathwork Diagnostics
It can be challenging to accurately diagnose the tissue of origin in metastatic, poorly differentiated, and undifferentiated tumors, even after imaging and extensive histological workup.  There is an increased need for high confidence tissue of origin diagnosis driven by the opportunity to prescribe more effective, less toxic, targeted therapies. Pathwork Diagnostics recently launched a new molecular test, the Tissue of Origin Test, that utilizes gene expression profiling to assist in the diagnosis of tissue of origin. Pathwork’s Tissue of Origin Test is extremely accurate, has been extensively validated in peer-reviewed publications, and should be used to complement traditional histological work-up in difficult to diagnose cases where there is uncertainty regarding the diagnosis. More information on the test, including soft copies of publications, is available at www.pathworkdx.com

Pfizer Oncology
FirstRESOURCE
(877) 744-5675;
FAX (877) 744-5473;
9:00AM-7:00PM Eastern Time
Aromasin, Camptosar, Ellence, Sutent
FirstRESOURCE provides insurance benefit verification, prior authorization, payer cover policy, appeals assistance, alternative sources of coverage, and patient support program information.

 

Roche Oncology
Oncoline
(800) 443-6676;
8:30AM-5:00PM Eastern Time
Kytril, Roferon-A, Vesanoid, Xeloda
Oncoline offers a range of reimbursement and literature search services, including third-party payer reimbursement information, coverage and benefits verification, billing codes and claims procedures, assistance with appeals, clinical literature searches, and enrollment information for Roche’s Medical Needs Program.

 

Sanofi Aventis Oncology
Eligard Reimbursement Hotline
(877) 354-4273;
FAX (866) 354-4273;
9:00AM-8:00PM Eastern Time
Eligard
The Hotline provides patient assistance and reimbursement support.

Hyalgan Reimbursement Hotline
(800) 992-9022;
FAX (866) 354-4273;
9:00AM-8:00PM Eastern Time
Hyalgan
The Hotline provides patient assistance and reimbursement support.

PACT+ Program
(800) 996-6626;
FAX (800) 996-6627;
www.pactplusonline.com;
9:00AM-8:00PM Eastern Time
Anzemet, Elitek, Eloxatin, Nilandron, Taxotere
The PACT+ Program provides patient assistance, alternative resources, and reimbursement support to oncology patients and providers. The PACT+ Provider Portal is a secure web site accessible only to healthcare provides and reimbursement personnel who participate in the PACT+ Program on behalf of their practice’s needy patients. This tool is the first of its kind in oncology and offers improved workflow processes related to reimbursement and patient assistance program (PAP) information, such as the ability to streamline and prioritize PAP caseload, complete enrollment applications online, receive alerts and reminders about specific patient cases, track PAP product shipments, and easily access all patient related information including patient history, alerts/reminders, insurance benefit summaries, shipments, attachments, and case histories. To register for the PACT+ Provider Portal, visit www.pactplusonline.com or call (800) 996-6626.

Valuable Links & Resources
APAP Patient Application
Updated Abraxane information
Disease Resources
 
 
 
 
 
 

Updated Abraxane Patient Assistance Program Income Guidelines

     It’s my pleasure to communicate the new Abraxane® patient assistance program guidelines.  Since my last visit the Abraxis Patient Access Program (APAP) income guidelines have increased from a gross family household income of $75,000 to $100,000.

This program change was effective Monday, July 14, 2008 for both your uninsured and underinsured Abraxane® patients. All other program guidelines remain unchanged:

  • Permanently residing in the US or US territories
  • Any diagnosis deemed medically necessary by the MD
On the left is a copy of the APAP Patient Application. Additional forms can be found in the ARC section of www.Abraxane.com  or by contacting the ARC of Support Reimbursement Services at (800) 564 – 0216, option 3, M-F from 8 am – 8 pm ET.

Abraxane Patient Assistance Program Income Guidelines
The Abraxane® patient assistance program guidelines.  The Abraxis Patient Access Program (APAP) income guidelines are a gross family household income of  $100,000. This program is effective for both uninsured and underinsured Abraxane® patients. All other program guidelines remain unchanged:

  • Permanently residing in the US or US territories
  • Any diagnosis deemed medically necessary by the MD

Please go to this link for a copy of the APAP Patient Application ARCPATIENT ENROLLMENT
Additional forms can be found in the ARC section of www.Abraxane.com  or by contacting the ARC of Support Reimbursement Services at (800) 564 – 0216, option 3, M-F from 8 am – 8 pm ET.  

For a copy of the updated package insert please go to UPDATED ASSYX1A .

Please don’t hesitate to contact Kristinna Tiong, West Regional Reimbursement Manager, Abraxis Oncology, a Division of Abraxis BioScience, Inc., phone: 619/434-4640; mobile phone: 619/929-4539; fax: 619/434-4641; ktiong@abraxisbio.com , if you have any questions regarding Abraxane® reimbursement or the Abraxis Patient Access Program (APAP).


AstraZeneca Cancer Support Network (AZ CSN)

(866) 922-9276
Monday-Friday 8:00 AM to 8:00 PM Eastern Time.

AZ CSN is a comprehensive service platform for physicians and patients
designed to meet informational needs, provide access to product, and
address coverage issues.  Specially trained Registered Nurses,
Pharmacists, and Reimbursement Specialists are available to personally
address our customers needs including a gateway to our AZ & Me
Prescription Savings Program. 

More information can be obtained by visiting:  www.azcsn.net

At AstraZeneca, we believe it's not enough for us to simply make medicines. We have to make sure that the people who need those medicines can get them. It's why we've offered patient assistance programs for over 30 years.

Since 1978, we've worked hard to better understand the needs of patients and the healthcare system so that our patient assistance programs can make a difference. In 2008, AstraZeneca helped over 440,000 people fill
2.7 million prescriptions resulting in more than $600 million of savings to patients.

Our commitment to improving health isn't just through our innovations in the lab; it's also through knowing the people who use our medicines and helping them get these medicines when they need them."


Celgene Corporation is pleased to announce that VIDAZA® (azacitidine for injection) has received approval from the US Food and Drug Administration to include survival data for patients with higher-risk myelodysplastic syndromes (MDS) in its prescribing information.  A PDF file of the updated Vidaza prescribing information is attached to this message.  For more information, please visit www.vidaza.com.

PLEASE NOTE:
VIDAZA is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

IMPORTANT SAFETY INFORMATION:

  • VIDAZA is contraindicated in patients with a known hypersensitivity to azacitidine or mannitol and in patients with advanced malignant hepatic tumors
  • In Studies 1 and 2, the most commonly occurring adverse reactions by SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%), and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), and malaise (10.9%). In Study 3, the most common adverse reactions by IV route also included petechiae (45.8%), weakness (35.4%), rigors (35.4%), and hypokalemia (31.3%)
  • In Study 4, the most commonly occurring adverse reactions were thrombocytopenia (69.7%), neutropenia (65.7%), anemia (51.4%), constipation (50.3%), nausea (48.0%), injection site erythema (42.9%), and pyrexia (30.3%). The most commonly occurring Grade 3/4 adverse reactions were neutropenia (61.1%), thrombocytopenia (58.3%), leukopenia (14.9%), anemia (13.7%), and febrile neutropenia (12.6%)
  • Because treatment with VIDAZA is associated with anemia, neutropenia, and thrombocytopenia, complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle
  • Because azacitidine is potentially hepatotoxic in patients with severe preexisting hepatic impairment, caution is needed in patients with liver disease. In addition, azacitidine and its metabolites are substantially excreted by the kidneys and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function
  • VIDAZA may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be apprised of the potential hazard to the fetus. Men should be advised not to father a child while receiving VIDAZA
  • Nursing mothers should be advised to discontinue nursing or the drug, taking into consideration the importance of the drug to the mother.

I you have any questions regarding this message, please contact:

George K. Malouly
National Account Management
Celgene Corporation
310.859.0175 office
gmalouly@celgene.com
http://www.celgene.com


      The Celgene Patient Support Coordinator (PSC) is a dedicated central point of contact helping healthcare providers and patients to navigate the challenges of reimbursement, provide information about co-pay assistance and to answer general questions about Celgene products.
      Celgene, is committed to developing safe and effective therapies for treating cancer and blood diseases. Celgene wants to ensure that their medications and services are readily accessible to patients and healthcare providers.
     
The benefits of the PSC® program and the Celgene commitment to patients:
Dedicated, central point of contact
Can locate co-pay assistance programs and services
Can assist with insurance claims and appeals
Can address opportunities for free product

      Recently, Oncology Business Review published the results of their exclusive market research study on patient assistance programs—those programs that provide help to uninsured and underinsured patients, programs like our PSC® program. Here are the highlights of their results:

  1. These programs had a positive influence on prescribing not just for the specific patient receiving assistance, but also for future patients
  2. Cost to the patient was cited by oncologists as the top reason NOT to prescribe a drug
  3. Oncologists identified Celgene as being tied for #2 for having the best program in the industry!
  4. The 3 top reasons that determined “best” in the oncologists’ minds were:

Easy/liberal enrollment
Easy access to needed products
Easy to use

  1. Oncologists use these programs because:

Programs are helpful to patients
Easy access/use 

      If you are interested in receiving more information regarding the PSC® Program, please contact a live Patient Support Coordinator  @ 800.931.8691, your Celgene Representative or George K. Malouly, National Account Management

310.859.0175 office, gmalouly@celgene.com.
http://www.celgene.com

VELCADE Reimbursement Assistance Program

This program is a full-service hotline for healthcare providers, patients and caregivers. Reimbursement Specialists verify health insurance coverage and eligibility; obtain pre-authorization; assess each patient’s drug coverage; and clarify any co-payments obligations patients may have relative to VELCADE® (bortezomib) for Injection. In cases where patients have insufficient health insurance coverage, Reimbursement Specialists will help determine if alternative funding sources for VELCADE are available. If no other sources of drug coverage can be identified, patients will be evaluated for the Velcade Patient Assistance Program and, if eligible, will receive VELCADE free of charge.

Reimbursement Specialists are available Monday through Friday from 9:00 am to 7:00 pm ET by calling 1-866-VELCADE (1-866-835-2233).

 

Millennium: The Takeda Oncology Company

Millennium Pharmaceuticals, Inc. was established in 1993 in Cambridge, Massachusetts as a genomics company and since has grown into a fully integrated biopharmaceutical organization. The Company was acquired by Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company, and renamed Millennium: The Takeda Oncology Company in May 2008. As a wholly-owned and independent subsidiary, Millennium operates as Takeda’s Global Center of Excellence in Oncology. Today, Millennium is committed to discovering and developing innovative new therapies that fundamentally improve the lives of people with cancer.

In 2009, Millennium announced its new vision: We Aspire to Cure Cancer. The Company focuses on innovation and strives to cure cancer and one day be a leading global oncology company. Currently, Millennium has a robust clinical development pipeline of innovative product candidates focused in oncology. Millennium celebrates and entrepreneurial spirit and culture of people who work with a sense of urgency to deliver medicines to patients with cancer worldwide through our science, innovation and passion.

Amgen (NASDAQ:AMGN), a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.

Amgen Assist
www.amgenassist.com  
1-800-272-9376
9:00AM-8:00PM Eastern Time

Amgen Assist™ gives healthcare professionals and patients a
single destination for user-friendly online tools and forms and
makes it easier to find the appropriate program for each
patient’s unique needs.

Use Amgen Assist™ for:
• Insurance verification
• Prior authorization
• Patient assistance program information
• Billing and claims processing support

The Safety Net Foundation
(888) 762-6436
FAX (866) 549-7239
9:00AM-8:00PM Eastern Time

A nonprofit foundation supported by Amgen that provides
qualified uninsured patients with Amgen medicines at no cost.

AZandMe direct link (all forms of patient assistance)

 <<www.azandme.com.url>>
Joan Milazzo
Oncology Customer Account Leader, West Region VM 866.822.797.2420 x66528 Cell 626.665.1447

Abraxane, J9264

Abraxis Bioscience; The Abraxis Resource Center, ARC of Support (800) 564-0216

The ARC of Support is a comprehensive program that provides a broad range of services (i.e., medical information, reimbursement and patient assistance, drug safety, product quality) for healthcare professionals caring for patients undergoing treatment with Abraxane.  Patient assistance is provided through the Abraxis Patient Access Program (APAP) (800) 564-0216, option 3 Mon-Fri 8:00 AM - 8:00 PM Eastern Time. APAP consists of two components—one for insured patients that havebeen treated with Abraxane whereclaims have been denied by theirinsurers, and the other for uninsuredpatients that receive treatment with Abraxane. More information can be obtained at www.abraxane.com or www.abraxisbio.com.

About Abraxis BioScience, Inc.  

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

The Eisai Reimbursement Hotline can help customers with reimbursement support, billing, coding, insurance verification and /or pre-certification, prior-authorization assistance, letters of medical necessity, claim denial appeal support, co-pay assistance and alternate coverage for all Eisai Oncology products-  Aloxi, Dacogen, Fragmin, Ontak, Gliadel, and Targretin.

The Eisai Assistance Program also offers Patient Assistance Programs to serve the indigent, underinsured and uninsured.

Eisai Oncology Assistance Program Hotline contact information is:

Phone #  1-866-61-Eisai
Hours of Operation:  Monday - Friday  8:00 a.m. - 8:00 p.m. EST

Fax#  1-866-57-Eisai

Genentech BioOncology
Genentech Access Solutions
(888) 249-4918;
www.genentechaccesssolutions.com;
Avastin, Herceptin, Rituxan, Tarceva
Genentech Access Solutions
 provides one-stop access to a broad array of reimbursement information, and support and services for patients so that they can focus on treatment. In addition to providing information about co-pay assistance through independent public charities, Genentech Access Solutions can also help with common reimbursement challenges, insurance appeals and coverage denials, and referrals to the Genentech Access to Care Foundation. For coverage and reimbursement services, visit www.genentechaccesssolutions.com/
docs/av/ASEEnrollment.pdf; for patient assistance, visit www.genentechaccesssolutions.com/
docs/av/GATCFEnrollment.pdf.

Avastin Patient Assistance Program

(888) 249-4918;
FAX (888) 249-4919;
6:00AM-5:00PM Pacific Time
The Avastin Patient Assistance Program is designed to limit the overall annual cost of Avastin for eligible patients receiving treatment for FDA-approved indications. Participation in the Program provides a voluntary opportunity for physicians and eligible patients who reach an annual charge of 10,000mg to receive free Avastin from Genentech for the remainder of the 12-month period. The Program is open to all patients receiving Avastin (regardless of insurance coverage) with a household adjusted gross income of up to $100,000. Patients must be receiving Avastin for an FDA-approved indication.
qualified uninsured patients with Amgen medicines at no cost.

Allos Therapeutics, Inc.
Allos Support for Assisting Patients (ASAP) Program
(877) ASAP102 (272-7102);
FAX (877) 801-0777;
9:00AM-8:00PM Eastern Time
Folotyn
ASAP (Allos Support for Assisting Patients) is a program designed to provide you with the tools to help make reimbursement easy to understand and more manageable. Services include benefit investigations, pre-authorizations, pre-determinations, appeals, drug replacement, alternative sources of coverage, and finding co-pay assistance. Visit www.getasapinfo.com for more information and to access the interactive map that provides available reimbursement information by state, specific to Medicare, Medicaid, and commercial payers.
---------------------------------------------------------------------
Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. FOLOTYN™ (pralatrexate injection) is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. The Company is headquartered in Westminster, CO. For additional information, please visit www.allos.com

sanofi-aventis
PACT+
Monday–Friday
9 am – 8 pm, ET
1.800.996.6626
www.pactplusonline.com

 

Patient Assistance and Reimbursement Services
The PACT+ program provides patient assistance, alternative resources and reimbursement support to oncology patients and providers. Reimbursement Counselors are available to answer questions about Eloxatin® (oxaliplatin injection), Taxotere® (docetaxel), Elitek® (rasburicase), Anzemet® (dolasetron mesylate) and Nilandron® (nilutamide).

sanofi-aventis Oncology has established this toll-free patient assistance hotline as a resource to health care professionals, patients, family members, and payers. All callers receive personalized assistance from reimbursement counselors, who are specially trained to address coding questions, coverage and benefit verification, claim submission, payment policies, and other reimbursement issues regarding sanofi-aventis oncology products.

 

PACT+Provider Portal
The PACT+ Provider Portal is a secure web site accessible only to healthcare providers and reimbursement personnel who participate in the PACT+ program on behalf of their practice's needy patients. This tool is the first of its kind in oncology and offers improved workflow processes related to reimbursement/patient assistance program information, such as the ability to: streamline and prioritize PAP caseload, complete enrollment applications online, receive alerts and reminders about specific patient cases, track PAP product shipments, and easily access all patient-related information, including patient history, alerts/reminders, insurance benefit summaries, shipments, attachments, and case history.

 

To register for the PACT+ Provider Portal, please visit www.pactplusonline.com or call PACT+ at 1.800.996.6626 and select Option 2.

Please Note: Access to the PACT+ Provider Portal is restricted to physicians, staff, and administrators who currently have permission to view patients' charts and their PHI. The portal is not accessible to sanofi-aventis employees or to patients enrolled in the PACT+ Program. There are no charges associated with registration or use of this portal. 

To Download Sanofi-Aventis Patient and Practice Reimbursement Tools and Access the Sanofi-Aventis Website: Click here http://www.oncology.sanofi-aventis.us/


Dear MOASC Members,
Genentech has implemented the BioOncology Co-Pay Card Program to assist eligible patients with their insurance co-payments for our infused products Avastin® (bevacizumab), Herceptin® (trastuzumab), and RITUXAN® (Rituxumab).  This complements our existing Co-Pay Card Program for Tarceva® (erlotinib) patients.
This program is in alignment with Genentech’s corporate commitment to ensure that all eligible patients have access to the therapies they need.
How does the Genentech BioOncology Co-Pay Card Program help eligible patients?
Genentech will pay 80% of the remaining co-pay, up to $4,000 per eligibility period, after the patient pays the first $100 plus 20% of the co-pay per treatment or infusion of their BioOncology therapy.
Who is eligible for the Genentech BioOncology Co-Pay Card Program?
Patient Eligibility Terms:
§  Covered by private insurance (nongovernmental)
§  Annual household Adjusted Gross Income of $100,000 or less
§  Co-pay over $100
§  Age 18 years or older
§  Prescribed an infused BioOncology therapy for an FDA-approved use
Who is not eligible for the Genentech BioOncology Co-Pay Card Program?
Patient Ineligibility Terms:
§  Participating in Medicare, Medicaid, Medigap, VA, DoD, or Tricare (or any other federally- or state-funded benefit programs)
§  Uninsured
§  Currently residing or receiving services in Massachusetts
§  Currently participating in the Genentech® Access to Care Foundation
 How does a patient get started?
1.     The patient works with the physician’s office to:
Ø  Complete the Statement of Medical Necessity (SMN) and Patient Authorization of Notification (PAN) forms, which can be found at BioOncologyAccessSolutions.com
Ø  Call Genentech Access Solutions at 888-249-4918 to verify eligibility and confirm the patient’s age, address, household income, insurance status, and diagnosis
2.     The physician receives enrollment approval once the enrollment is finalized.
3.     The patient receives treatment and the co-pay benefit.
Please don’t hesitate to contact me directly with questions.
Best regards,
Jennifer Fraga Schroeder
Reimbursement Manager
415.740.5445

 

AVASTIN SAFETY INFORMATION

Indications                                                                                                                 
Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with
interferon alfa.
Avastin is indicated for the first-line treatment of unresectable, locally advanced,
recurrent or metastatic non–squamous non–small cell lung cancer in combination
with carboplatin and paclitaxel.
Avastin is indicated for the first- or second-line treatment of patients with metastatic
carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil–
based chemotherapy.

Boxed WARNINGS
Gastrointestinal perforation: Occurs in up to 2.4% of Avastin-treated patients. Discontinue Avastin for gastrointestinal perforation.
Surgery and wound healing complications: Discontinue in patients with wound dehiscence. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed.
Hemorrhage: Severe or fatal hemorrhage, hemoptysis, gastrointestinal bleeding, CNS hemorrhage, and vaginal bleeding are increased in Avastin-treated patients. Do not administer Avastin to patients with serious hemorrhage or recent hemoptysis.

Additional serious adverse events
Serious adverse events, in some instances resulting in fatality, associated with Avastin are non-GI fistula formation and arterial thromboembolic events (ATEs). Additional serious adverse events associated with Avastin were hypertension, reversible posterior leukoencephalopathy syndrome (RPLS), proteinuria, and infusion reactions.

Most common adverse events
The most common adverse reactions observed in Avastin patients at a rate >10% and at least twice the control arm rate were epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis. Across all studies, Avastin was discontinued in 8.4% to 21% of patients because of adverse reactions.

 

Important safety information—AVOREN
In mRCC, the most common grade 3–5 adverse events in AVOREN, occurring at a ≥2% higher incidence in Avastin-treated patients vs controls, were fatigue (13% vs 8%), asthenia (10% vs 7%), proteinuria (7% vs 0%), hypertension (6% vs 1%), and hemorrhage (3% vs 0.3%).

Important safety information—Study E4599

In NSCLC, grade 3–5 (nonhematologic) and grade 4–5 (hematologic) adverse events in Study E4599 occurring at a >2% higher incidence in Avastin-treated patients vs controls were neutropenia (27% vs 17%), fatigue (16% vs 13%), hypertension (8% vs 0.7%), infection without neutropenia (7% vs 3%), venous thrombus/embolism (5% vs 3%), febrile neutropenia (5% vs 2%), pneumonitis/pulmonary infiltrates (5% vs 3%), infection with grade 3 or 4 neutropenia (4% vs 2%), hyponatremia (4% vs 1%), headache (3% vs 1%), and proteinuria (3% vs 0%).

Important safety information—Study 2107
The most common grade 3–4 events in Study 2107, which occurred at a ≥2% higher incidence in the Avastin plus IFL vs IFL groups, were asthenia (10% vs 7%), abdominal pain (8% vs 5%), pain (8% vs 5%), hypertension (12% vs 2%), deep vein thrombosis (9% vs 5%), intra-abdominal thrombosis (3% vs 1%), syncope (3% vs 1%), diarrhea (34% vs 25%), constipation (4% vs 2%), leukopenia (37% vs 31%), and neutropenia (21% vs 14%).

 

Important safety information—Study E3200
The most common grade 3–5 (nonhematologic) and 4–5 (hematologic) events in Study E3200, which occurred at a higher incidence (≥2%) in the Avastin plus FOLFOX4 vs FOLFOX4 groups, were diarrhea (18% vs 13%), nausea (12% vs 5%), vomiting (11% vs 4%), dehydration (10% vs 5%), ileus (4% vs 1%), neuropathy–sensory (17% vs 9%), neurologic–other (5% vs 3%), fatigue (19% vs 13%), abdominal pain (8% vs 5%), headache (3% vs 0%), hypertension (9% vs 2%), and hemorrhage (5% vs 1%).

 

Click here to see full Prescribing Information, including Boxed WARNINGS, and additional safety information.

Avastin full Prescribing Information

HERCEPTIN SAFETY INFORMATION

Indications
Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or nodenegative (ER/PR-negative or with one high-risk feature*) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

*ER/PR-negative, tumor size >2 cm, age <35 years, or histological and/or nuclear grade 2 or 3.

 

Metastatic indications
Herceptin is indicated:
∙ In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic
   breast cancer
∙ As a single agent for treatment of HER2-overexpressing breast cancer in patients who have
   received one or more chemotherapy regimens for metastatic disease

Important Safety Information
Boxed WARNINGS and Additional Important Safety Information
Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting
as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion
reactions and pulmonary toxicity have occurred; fatal infusion reactions have been
reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. Herceptin can
cause oligohydramnios and fetal harm when administered to a pregnant woman. The most
common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion
reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia,
anemia, and myalgia.

Click here to see full Prescribing Information, including Boxed WARNINGS, and additional safety information.

Herceptin full Prescribing Information


TARCEVA SAFETY INFORMATION

Important Safety Information:

  • There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer or other advanced solid tumors.
  • Cases of hepatic failure, hepatorenal syndrome, acute renal failure (all including fatalities), and renal insufficiency have been reported during use of Tarceva.
  • Gastrointestinal perforation (including fatalities) has been reported in patients receiving Tarceva.  
  • Bullous, blistering and exfoliative skin conditions have been reported including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal.
  • In the pancreatic cancer trial, other serious adverse reactions associated with Tarceva plus gemcitabine and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia.
  • Corneal perforation and ulceration have been reported during use of Tarceva.
  • When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding. Tarceva is pregnancy category D.
  • The most common adverse reactions in patients with NSCLC receiving Tarceva monotherapy 150 mg were rash and diarrhea.
  • The most common adverse reactions in patients with pancreatic cancer receiving Tarceva 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea.

Click here to see full Prescribing Information.

Tarceva full Prescribing Information

 

RITUXAN SAFETY INFORMATION

Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL (DLBCL) in combination with CHOP or other anthracycline-based chemotherapy regimens

 

BOXED WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of RITUXAN are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of RITUXAN (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia.
 
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Click here to see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

RITUXAN full Prescribing Information

Jennifer Fraga Schroeder| BioOncology Field Reimbursement Manager | Managed Care Customer Operations
(415.740.5445 | (f: 866.686.5752 | * fraga.jennifer@gene.com |ýwww.gene.com

The Genomic Health Access Program (GAP) has been designed to assist patients and healthcare providers with any billing or reimbursement issues related to the Oncotype DX test. Payors representing more than 200 million lives cover Oncotype DX and have established favorable coverage policies for this groundbreaking technology. We can help with reimbursement support, billing, coding, insurance verification and /or pre-certification, prior-authorization assistance, letters of medical necessity, claim denial appeal support and co-pay assistance for Oncotype DX.

 The Genomic Health Assistance Program also offers Patient Assistance Programs to serve the indigent, underinsured and uninsured.

 Genomic Health Access Program contact information is: 

 Phone # 866-ONCOTYPE (866-662-6897) 

Hours of Operation:  Monday - Friday 8:00 a.m. - 8:00 p.m. EST


Corporate Member Profile

Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. We work to identify and control promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. Pharmacyclics has one approved molecule and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
At Pharmacyclics, we intend to create medicines that improve both the quality and duration of patient lives. This requires hard work, sacrifice, money, organization, communication, affinity for what we do and a willingness to be of service to others.
YOU&I Access
YOU&i Access™ program is a comprehensive, personalized support program from Pharmacyclics, Inc., and Janssen Biotech, Inc., designed to help make access simple, convenient, and easy. Patients or their provider may access YOU&i Access™ by visiting www.youandiaccess.com or calling 1-877-877-3536. YOU&i Access consists of two parts: YOU&i Start program which can provide access to our approved drug for patients who are experiencing insurance coverage decision delays; and YOU&i Instant Savings which allows patients on commercial insurance, and who meet eligibility requirements, to pay no more than $10 per month for our approved drug. YOU&i Access may also be utilized for benefit investigation to determine if our approved drug is covered, or help with prior authorization process at your request.
Pharmacyclics, Inc. has made some exciting changes to the YOU&i™ Instant Savings Program.  New and current eligible patients will benefit from a lower out-of-pocket cost per month and a higher yearly maximum benefit. 

  • Here are the changes:
    • Now $10 per month – changed from $25 per month.  All other program rules, including eligibility requirements, will remain.
    • Maximum yearly benefit will now be $24,600 or 25% of WAC (Wholesale Acquisition Cost) – that is an increase from $18,695 or 19% or WAC.
    • Program changes are effective immediately – eligible patients signed up today will pay $10 per month.
    • Patients that are currently enrolled in the program will pay $10 per month beginning with their next prescription

Contacts
All non-medical questions may be directed to John Logan at jlogan@pcyc.com. Any medical questions should be directed to www.pharmacyclicsmedinfo.com.
© 2008 - 2013 Medical Oncology Association of Southern California
P.O. Box 161   •    Upland, CA 91785
Phone: (909) 985-9061   •    Fax: (909) 985-8581   •   email: moasc@moasc.org

inland empire website design wow webs